The tariff classification of Clonidine Hydrochloride Extended-Release Tablets in dosage form, from India
Issued December 15, 2023 by U.S. Customs and Border Protection.
Tariff classification
HTS codes: 3004.90.9220
Headings: 3004
Product description
Clonidine Hydrochloride, imported in 0.1 mg extended-release tablets, is in a class of medications called centrally acting alpha-agonist hypotensive agents. It is used to treat high blood pressure by decreasing the heart rate and relaxing the blood vessels so that blood can flow more easily through the body. Clonidine Hydrochloride Extended-Release Tablets may also be used in the treatment of attention deficit hyperactivity disorder (ADHD).
CBP rationale
The applicable subheading for the Clonidine Hydrochloride Extended-Release Tablets in dosage form will be 3004.90.9220, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Cardiovascular medicaments.
Full text
N336754 December 15, 2023 CLA-2-30:OT:RR:NC:N3:138 CATEGORY: Classification TARIFF NO.: 3004.90.9220 Rosie Hipwell Bluepoint Labs 8 Eastgate Avenue Eastgate Business Park, CorkIreland RE: The tariff classification of Clonidine Hydrochloride Extended-Release Tablets in dosage form, from India Dear Ms. Hipwell: In your letter dated November 28, 2023, you requested a tariff classification ruling. Clonidine Hydrochloride, imported in 0.1 mg extended-release tablets, is in a class of medications called centrally acting alpha-agonist hypotensive agents. It is used to treat high blood pressure by decreasing the heart rate and relaxing the blood vessels so that blood can flow more easily through the body. Clonidine Hydrochloride Extended-Release Tablets may also be used in the treatment of attention deficit hyperactivity disorder (ADHD). The applicable subheading for the Clonidine Hydrochloride Extended-Release Tablets in dosage form will be 3004.90.9220, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Cardiovascular medicaments.” The rate of duty will be free. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided at https://hts.usitc.gov/current. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. The holding set forth above applies only to the specific factual situation and merchandise description as identified in the ruling request. This position is clearly set forth in Title 19, Code of Federal Regulations (CFR), Section 177.9(b)(1). This section states that a ruling letter is issued on the assumption that all of the information furnished in the ruling letter, whether directly, by reference, or by implication, is accurate and complete in every material respect. In the event that the facts are modified in any way, or if the goods do not conform to these facts at time of importation, you should bring this to the attention of U.S. Customs and Border Protection (CBP) and submit a request for a new ruling in accordance with 19 CFR 177.2. Additionally, we note that the material facts described in the foregoing ruling may be subject to periodic verification by CBP. This ruling is being issued under the provisions of Part 177 of the Customs and Border Protection Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, please contact National Import Specialist Judy Lee at [email protected]. Sincerely, Steven A. Mack Director National Commodity Specialist Division
More rulings on the same tariff codes
The tariff classification of Enoxaparin Sodium Injection in dosage form, from China
The tariff classification of Enoxaparin Sodium Injection in dosage form, from China
The tariff classification of Metoprolol Succinate Extended Release Tablets in dosage form, from India
The tariff classification of Scopolamine Transdermal System from Australia and Pitavastatin Tablets from India
The tariff classification of Labetalol Hydrochloride Injection in dosage form, from Italy
The tariff classification of Icosapent Ethyl Capsules in dosage form, from China, and the classification of Norelgestromin and Ethinyl Estradiol Transdermal System from Argentina and India
The tariff classification of Dofetilide Capsules in dosage form, from India
The tariff classification of Isosorbide Dinitrate Tablets in dosage form, from India
The tariff classification of Clopidogrel Bisulfate Tablets in dosage form, from India
The tariff classification of Diltiazem Hydrochloride ER Capsules in dosage form, from India
Searching CBP rulings the smart way
TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.
Book a demo →